Boston Scientific (NYSE:BSX) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Boston Scientific (NYSE:BSX) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03, FiscalAI reports. The business had revenue of $5.44 billion during the quarter, compared to analyst estimates of $5.36 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same quarter last year, the firm posted $0.75 earnings per share. Boston Scientific updated its Q3 2026 guidance to 0.800-0.820 EPS and its FY 2026 guidance to 3.280-3.320 EPS.

Here are the key takeaways from Boston Scientific’s conference call:

• Second-quarter results exceeded guidance, with organic revenue growth of 7% and adjusted EPS of $0.86, up 15% year over year and above the $0.82–$0.84 forecast range.
• Boston Scientific reduced its 2026 outlook to 5%–6% organic revenue growth and adjusted EPS of $3.28–$3.32, citing sharper-than-expected pressure in U.S. electrophysiology and a slowdown in WATCHMAN adoption.
• WATCHMAN growth is expected to decline mid- to high-single digits globally in the second half, while EP growth is expected to be flat; management also anticipates limited EPS growth and margin pressure in 2027.
• A company-wide restructuring program is expected to generate approximately $500 million in annualized savings by the end of 2029, with more than half realized by the end of 2027 and reinvestment directed toward priority growth areas.
• Management highlighted strong momentum in interventional cardiology, neuromodulation, interventional oncology, and vascular therapies, alongside longer-term catalysts including Penumbra, coronary IVL, FARAWAVE Ultra, ICE imaging, and potential MiRus TAVR assets.

Boston Scientific Stock Up 1.1%

Shares of BSX traded up $0.52 during mid-day trading on Wednesday, reaching $46.58. The company’s stock had a trading volume of 24,062,692 shares, compared to its average volume of 18,127,271. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.22. Boston Scientific has a 12-month low of $42.20 and a 12-month high of $109.50. The stock has a market cap of $69.24 billion, a PE ratio of 19.51, a price-to-earnings-growth ratio of 0.87 and a beta of 0.58. The company’s 50 day moving average is $46.78 and its 200 day moving average is $63.10.

Analyst Upgrades and Downgrades

BSX has been the subject of several recent research reports. The Goldman Sachs Group set a $71.00 price target on shares of Boston Scientific in a research report on Thursday, May 28th. Needham & Company LLC reduced their price objective on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Truist Financial lowered their target price on Boston Scientific from $64.00 to $62.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $55.00 price target (down from $75.00) on shares of Boston Scientific in a research report on Thursday, May 28th. Finally, UBS Group reiterated a “buy” rating and issued a $74.00 price objective (down from $95.00) on shares of Boston Scientific in a research note on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $78.40.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific exceeded expectations with adjusted EPS of $0.86 versus the $0.83 consensus and revenue of $5.442 billion versus $5.36 billion. Revenue increased 7.5% year over year, while adjusted EPS rose from $0.75 in the prior-year quarter. Boston Scientific Announces Second-Quarter Results
• Positive Sentiment: Growth was broad-based: Cardiovascular sales increased 8.3%, with particularly strong reported growth in APAC and LACA. U.S. sales rose 6.2%, EMEA 6.1%, APAC 11.2% and LACA 22.4%, while margin expansion also supported the quarterly performance. Boston Scientific Q2 Earnings and Revenue Beat
• Positive Sentiment: The company completed a $2 billion accelerated share repurchase, buying back approximately 40 million shares. It also invested $1.5 billion for a roughly 34% stake in MiRus and an option to acquire its TAVR business, potentially strengthening Boston Scientific’s structural-heart portfolio. Boston Scientific Q2 Revenue Report
• Neutral Sentiment: Boston Scientific received FDA 510(k) clearance for its TruSelect 2.6 Microcatheter, adding a new commercial opportunity, although the immediate financial impact is unclear.
• Negative Sentiment: Management reduced 2026 adjusted EPS guidance to $3.28-$3.32 from $3.34-$3.41 and forecast revenue of $21.2-$21.4 billion, below the approximately $21.6 billion consensus. Third-quarter guidance of $0.80-$0.82 EPS and $5.2-$5.3 billion revenue also trails analyst expectations. Boston Scientific Lowers Annual Profit Forecast
• Negative Sentiment: The outlook reduction reflects slower demand for the Watchman heart device, product-growth moderation and increased competition. A global restructuring plan is expected to involve headcount reductions and $700 million-$800 million of costs through 2029, although management targets approximately $500 million in annual savings. Boston Scientific Cuts Outlook Ahead of Restructuring
• Negative Sentiment: UBS lowered its price target to $74 from $95 while retaining a Buy rating, signaling reduced near-term expectations despite confidence in Boston Scientific’s longer-term prospects. UBS Adjusts Boston Scientific Price Target

Insider Activity at Boston Scientific

In related news, Director David C. Habiger acquired 2,250 shares of the firm’s stock in a transaction on Wednesday, May 20th. The stock was bought at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the completion of the purchase, the director directly owned 13,878 shares of the company’s stock, valued at approximately $776,057.76. The trade was a 19.35% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The shares were purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the transaction, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired 9,800 shares of company stock valued at $554,012 over the last three months. 0.34% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Garton & Associates Financial Advisors LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth approximately $26,000. Swiss RE Ltd. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $26,000. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the second quarter worth about $26,000. Sfam LLC purchased a new position in shares of Boston Scientific during the fourth quarter worth about $29,000. Finally, Pin Oak Investment Advisors Inc. purchased a new position in shares of Boston Scientific during the third quarter worth about $41,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific declared that its board has initiated a stock buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares buyback programs are generally an indication that the company’s board believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.